Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba-Geigy Pharmaceuticals

Division of Novartis AG

Latest From Ciba-Geigy Pharmaceuticals

Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints

Intercept is aiming to file obeticholic acid for accelerated approval in two liver disease indications and is mining clinical outcomes data to support new surrogate endpoints with the help of a clinical network dubbed the “Supergroup.”

BioPharmaceutical Clinical Trials

Exclusive: Rebuilding Ranbaxy – CEO Says Quality Compliance Trumps Achieving Growth Targets

Undaunted by a spate of negative news, Ranbaxy CEO Arun Sawhney says his mandate is clear: to build a strong reputation for Ranbaxy. In a discussion with PharmAsia News, Sawhney says he regrets the errors of the past that led to quality lapses, but says changes have been made to avoid similar fumbles in the future.

BioPharmaceutical Asia Pacific

Too Many Drugs, Too Little Value in CV Conditions

With the potential to treat multiple indications, a flood of cardiovascular drugs with purportedly novel mechanisms of action are expected to hit the market within 24 months. But because of the rapid progress in treating heart disease, what was novel years ago now appears mundane, diminishing the value of scientific breakthroughs that used to assure success.
BioPharmaceutical Medical Device

New Players in Big Pharma Dealmaking

In spite of biotech’s weakness on Wall Street, dealmaking in discovery research has been surprisingly rich in recent months, in part thanks to a group of drug companies new to dealmaking or with revived dealmaking programs. Most partners are not seeking to capitalize on biotech’s weakness. Instead, they aim to fill gaps in their pipelines with novel compounds for a value-sensitive marketplace.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Douglas Watson, Pres.
    William Sheldon, SVP, Marketing
    Jefferey F McKelvy, PhD, VP, Development
  • Contact Info
  • Ciba-Geigy Pharmaceuticals
    Phone: (908) 277-5000
    556 Morris Avenue
    Summit, NJ 07901
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register